Therapeutic Dose Range of Valproate-Induced Hyperammonemic Encephalopathy: A Case Report / 대한정신약물학회지
Korean Journal of Psychopharmacology
;
: 61-64, 2015.
Artículo
en Coreano
| WPRIM
| ID: wpr-111030
ABSTRACT
We report a case of a 34-year-old woman who was in temporary delirium and hyperammonemia during treatment of bipolar affective disorder with valproate. Patient showed delirium after 20 days of treatment, while the serum valproate level was within the therapeutic range without any sign of hepatic insufficiency. However, the patient had increased serum ammonia level (121 microg/mL), and valproate was discontinued due to suspicion of valproate-induced hyperammonemic encephalopathy (VHE). Serum valproate level was normalized with reduced delirium after valproate has been discontinued. Few VHE in psychiatric literature has been documented, because of possible confusion between VHE and preexisting psychiatric symptoms. Clinicians should be cautious about the potential risk for hyperammonemic encephalopathy caused by valproate medication.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Ácido Valproico
/
Trastornos del Humor
/
Hiperamonemia
/
Delirio
/
Insuficiencia Hepática
/
Amoníaco
Límite:
Adulto
/
Femenino
/
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Psychopharmacology
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS